



Til: MN- fakultetsstyret

Sakstype: Vedtakssak
Saksnr.: 11/25
Møtedato: 11.03.2025
Notatdato: 25.02.2025
Saksbehandler: Cecilie M. Sundet

Oppnevning av eksternt styreremedlem ved Institutt for Informatikk

Bakgrunn

Normalregler for institutter §2-2 angir at eventuelle eksterne representanter til instituttstyret oppnevnes av fakultetet.

Hovedproblemstillinger

Institutt for informatikk har de senere årene hatt en ordning med eksternt styremedlem og vi ønsker å fortsette med det. Vi ber om at Tarjei Hveem, Leder for Institutt for Kreftgenetikk og Informatikk ved OUS, oppnevnes som eksternt styremedlem ved Institutt for informatikk.

Vedtaksforslag

Fakultetsstyret oppnevner Tarjei Hveem som ekstern representant og medlem i styret for Institutt for informatikk for perioden 01.01.2025 -31.12.28.

Vedlegg

- Vedlegg 1: Begrunnelse fra instituttleder Ole Christian Lingjærde
- Vedlegg 2: CV for Tarjei Hveem

Oslo, 24. februar 2025

Ekstern representant i Styret ved Institutt for Informatikk: forslag til kandidat

Det skal velges en ekstern representant til Styret ved Institutt for Informatikk for perioden 2025-2028. Jeg ønsker å fremme Tarjei Hveem, Leder for Institutt for Kreftgenetikk og Informatikk ved OUS, som vår kandidat.

Hveem (f. 1979) har en mastergrad i informatikk fra NTNU (2004) og en doktorgrad i informatikk fra Ifi, UiO (2017). Hans spesialkompetanse innenfor informatikkfeltet omfatter bildebehandling og utvikling/bruk av kunstig intelligens. Før han tok doktorgrad arbeidet han som programmerer ved NTNU og var deretter tilknyttet OUS som programmerer (2006-2015). Han var deretter enhetsleder for applikasjonsutvikling (2015-2023), seksjonsleder for anvendt informatikk (2023) og leder for Institutt for Kreftgenetikk og Informatikk (2023-).

Hveem har god forståelse for betydningen av og prosesser rundt ekstern finansiering med sin erfaring innen søking av slik finansiering og arbeidspakkeledelse i flere eksternt finansierte prosjekter, inkludert det høythengende NFR-finansierte Lighthouse-prosjektet DoMore! Han har et betydelig forskningsnettverk nasjonalt og internasjonalt, både innenfor akademia og mot næringslivet. Han har inngående kjennskap til fagfeltet informatikk, både fra praktisk side, fra forskningssiden og fra lederperspektiv. Ytterligere beskrivelse av Hveem er å finne i vedlagte CV.

Samlet sett mener jeg at Tarjei Hveem vil være meget godt egnet som ekstern styrerepresentant i Ifis styre.

Ole Christian Lingjærde
Ole Christian Lingjærde

Instituttleder, Institutt for Informatikk

Curriculum vitae

Personal information

First name, Surname:	Tarjei Sveinsgjerd Hveem		
Date of birth:	26.12.1979	Sex:	Male
Nationality:	Norwegian		
Researcher unique identifier(s) (ORCID, ResearcherID, etc.):	ORCID: 0000-0002-0327-5048		
URL for personal website:	https://www.ous-research.no/home/medicalinformatics/Group-members/12357 https://www.researchgate.net/profile/Tarjei-Hveem		

Education

Year	Faculty/department - University/institution - Country
2017	Ph.D. Institute for Cancer Genetics and Informatics, Oslo University Hospital, Department of Informatics, University of Oslo, Norway
2004	Master. Faculty of Informatics Technology and Electrical Engineering, Department of Computer Science, Norwegian University of Science and Technology, Norway

Positions - current and previous

Year	Job title – Employer - Country
2023-	Interim Director, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Norway
2023-2023	Head of Section for Applied Informatics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Norway
2015-2023	Unit leader for Application development, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Norway
2006-2015	Programmer, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Norway
2005-2006	Programmer, Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Norway

Career breaks

Year	Reason
Aug 2015 – Feb 2016	Parental leave
May – Sep 2012	Parental leave

Project management experience

Year	Project owner - Project - Role - Funder
2024-2027	Institute for Cancer Genetics and Informatics at OUS - Deep learning for risk stratification and identification of prognostic features in patients with colorectal metastasis. Leader of WP2: Deep learning model development. Member of the project advisory board. <i>Funded by South-Eastern Norway Regional Health Authority (HSØ).</i>
2024-2027	Institute for Cancer Genetics and Informatics at OUS - Improved risk stratification with artificial intelligence in patients with colorectal liver metastasis. Leader of WP3: Validation and dissemination. Member of the project advisory board. <i>Funded by the Norwegian Cancer Society.</i>
2023-2027	Institute for Cancer Genetics and Informatics at OUS - Learning from deep learning – Revealing how convolutional neural networks predict patient outcome. Principal Investigator. Member of the project steering committee. <i>Funded by the Norwegian Research Council.</i>
2022-2025	Institute for Cancer Genetics and Informatics at OUS - Artificial intelligence-based biomarkers in active surveillance of prostate cancer. Leader of WP5: Validation and dissemination. Member of the project advisory board. <i>Funded by South-Eastern Norway Regional Health Authority (HSØ).</i>
2021-2024	Institute for Cancer Genetics and Informatics at OUS - Polyp classification by artificial intelligence. Leader of WP3: Validation and dissemination. Member of the project steering committee. <i>Funded by the Norwegian Cancer Society.</i>
2020-2022	Institute for Cancer Genetics and Informatics at OUS - In silico pathology - from bench to bedside. Leader of WP4: Development of image standardisation method. <i>Funded by the Norwegian Research Council.</i>
2016-2021	Institute for Cancer Genetics and Informatics at OUS - DoMore! In silico Pathology - Improving diagnosis by utilizing Big Data and software-driven automation of pathology. Leader of WP4: Tissue section analysis. <i>Lighthouse project funded by the Norwegian Research council.</i>

Other relevant professional experiences

(E.g. institutional responsibilities, organisation of scientific meetings, membership in academic societies, review boards, advisory boards, committees, major research or innovation collaborations, other commissions of trust in public or private sector)

Year	Description - Role
2024	Presented «Digital pathology and AI – research at ICGI and the DoMore project» at the national meeting for department leaders in pathology, Gardermoen

2024	Presented «Machine learning and digital pathology at the institute for cancer genetics and informatics» at the department of pathology, OUS, Oslo
2024	Presented «AI-driven automation of diagnostics and individual prognosis» at PM strategy meeting OUS, Oslo
2024	Presented «Cancer prognosis with digital pathology and deep learning» at MedFys conference, Oslo
2023	Presented the DoMore!-project at the conference «How to implement and use self-developed AI-solutions in the healthcare service» arranged by NORA.ai and KIN (Artificial intelligence in Norwegian healthcare service) Oslo

Prizes and Awards

1. Co-author of article published in The Lancet that was awarded by Oslo University Hospital for excellent original research article published first half year of 2020
2. Co-author of article published in The Lancet Oncology that was awarded by Oslo University Hospital for excellent original research article published first half year of 2018

Relevant publications

1. **Deep learning for automated scoring of immunohistochemically stained tumour tissue sections – Validation across tumour types based on patient outcomes.** Kildal W, Cyll K, Kalsnes J, Islam R, Julbø FM, Pradhan M, Ersvær E, Sheperd N, Vlatkovic L, OSBREAC, Tekpli X, Garred Ø, Kristensen GB, Askautrud HA, Hveem TS, Danielsen HE. *Heliyon* 2024 July 10(13).
2. **A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.** Kleppe A, Skrede OJ, Raedt SD, Hveem TS, Askautrud HA, Jacobsen JE, Church DN, Nesbakken A, Shepherd NA, Novelli M, Kerr R, Liestøl K, Kerr DJ, Danielsen HE. *Lancet Oncol.* 2022 Sep;23(9):1221-1232.
3. **Automated assessment of CD8 + T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer.** Jiang D, Hveem TS, Glaire M, Church DN, Kerr DJ, Yang L, Danielsen HE. *EBioMedicine.* 2021 Sep; 71:103547.
4. **PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer.** Cyll K, Kleppe A, Kalsnes J, Vlatkovic L, Pradhan M, Kildal W, Tobin KAR, Reine TM, Wæhre H, Brennhovd B, Askautrud HA, Haug ES, Hveem TS, Danielsen HE. *Cancers (Basel).* 2021 Aug26;13(17):4291.
5. **Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer.** Ersvær E, Hveem TS, Vlatkovic L, Brennhovd B, Kleppe A, Tobin KAR, Pradhan M, Cyll K, Wæhre H, Kerr DJ, Danielsen HE. *Int J Cancer.* 2020 Aug 15;147(4):1228-1234.
6. **Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.** Skrede OJ, Raedt SD, Kleppe A, Hveem TS, Liestøl K, Maddison J, Askautrud HA, Pradhan M, Nesheim JA, Albrechtsen F, Farstad IN, Domingo E, Church DN, Nesbakken A, Shepherd NA, Tomlinson I, Kerr R, Novelli M, Kerr DJ, Danielsen HE. *Lancet.* 2020 Feb1;395(10221):350-360.
7. **Association between proportion of nuclei with high chromatin entropy and prognosis in gynecological cancers.** Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albrechtsen F, Danielsen HE. *J Natl Cancer Inst.* 2018 Dec1;110(12):1400-1408.

8. **Chromatin organisation and cancer prognosis: a pan-cancer study.** Kleppe A, Albrechtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE. *Lancet Oncol.* 2018 Mar;19(3):356-369.
9. **Changes in chromatin structure in curettage specimens identifies high-risk patients in endometrial cancer.** Hveem TS, Njølstad TS, Nielsen B, Syvertsen RA, Nesheim JA, Kjæreng ML, Kildal W, Pradhan M, Marcickiewicz J, Tingulstad S, Staff AC, Haugland HK, Engh ME, Oddenes K, Rokne JA, Tjugum J, Lode MS, ENITEC network/ MoMaTEC study group, Amant F, Werner HM, Albrechtsen F, Liestøl K, Salvesen HB, Trovik J, Danielsen HE. *Cancer Epidemiol Biomarkers Prev.* 2017 Jan;26(1):61-67.
10. **Chromatin changes predict recurrence after radical prostatectomy.** Hveem TS, Kleppe A, Vlatkovic L, Ersvær E, Wæhre H, Nielsen B, Kjær MA, Pradhan M, Syvertsen RA, Nesheim JA, Liestøl K, Albrechtsen F, Danielsen HE. *Br J Cancer* 2016 April 114, 1243–1250.